A Phase 2 interventional study of Doxycycline 0.6 mg/kg/day and Doxycycline 1.2 mg/kg/day in Acne Vulgaris, sponsored by Warner Chilcott. Completed at 23 sites in United States. Open to participants aged 12 Years to 45 Years. Per ClinicalTrials.gov, last updated 2013-04-22.
Sponsored by Warner Chilcott (part of AbbVie) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing doxycycline in Acne Vulgaris — 2 open to participants now, 3 under way, none of them phase 3. Doxycycline · Acne Vulgaris.
Among the 12 studies testing doxycycline in Acne Vulgaris, this one is the 2nd largest by enrollment, is one of 2 that started in 2008, is one of 2 in phase 2, and was the 2nd registered.
791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.
Browse Acne Vulgaris studies →2 of the 12 studies testing doxycycline in Acne Vulgaris are open now, in 2 countries. Recruiting first, the newest first:
Integrative Skin Science and Research · Sites in United States
Ages 9+ · Healthy volunteers
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh · Sites in Bangladesh
Ages 18+
By country, each count listing its studies:
Doxycycline: first FDA approval 1967 (VIBRAMYCIN). What it is approved for, and how studies give it, is on its page →
Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.
This study: 12 Years to 45 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 5 · Phase 3 2 · Phase 4 6
First in 2005; this study’s year is marked. 2 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 257 is above the median of 70 across 673 interventional studies indexed under Acne Vulgaris.
Median enrollment 47 across the 12 interventional studies. Of the 7 that completed or were terminated, 7 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 12 have an industry lead sponsor. The 10 most frequent:
This study is registered under Warner Chilcott, one of the names counted as AbbVie. Under that name alone:
Warner Chilcott is the lead sponsor of 58 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
17 studies in Acne Vulgaris by AbbVie: none open now, none under way, none of them phase 3. Of 15 finished, 12 (80%) have results posted.
Among the 17 studies in Acne Vulgaris by AbbVie, this one is the 6th largest by enrollment, is one of 4 that started in 2008, is the only one in phase 2, and was the 3rd registered.
AbbVie’s Acne Vulgaris studies by the year they started, since 2005.
2 of the studies testing doxycycline in Acne Vulgaris that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02713607University of California, DavisLipidome and Microbiome Profile of Acne | 2027-01 |
| NCT07544251Integrative Skin Science and ResearchComparing Sarecycline and Doxycycline Effects on the Skin and Gut Bacteria in Acne. | 2027-04 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies testing doxycycline in Acne Vulgaris, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 17 in Acne Vulgaris:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Randomized, multi-center, double-blind, placebo-controlled 12-week study to assess the safety and efficacy of 3 doses of an oral formulation of Doxycycline oral tablets using the Investigator's Global Assessment (IGA) score and the absolute change from baseline in inflammatory lesion count in patients with moderate to severe facial acne vulgaris. Additionally, the absolute change from baseline in non-inflammatory and total lesions of the active study medication to placebo will be evaluated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Doxycycline dosed at 40 mg/day to subjects of appropriate weights
Drug: Doxycycline 0.6 mg/kg/day
Doxycycline dosed at 80 mg/day to subjects of appropriate weights
Drug: Doxycycline 1.2 mg/kg/day
Doxycycline dosed at 160 mg/day to subjects of appropriate weights
Drug: Doxycycline 2.4 mg/kg/day
Drug: Placebo
Drug page: Doxycycline
doxycycline 40 mg/day, oral, 12 weeks
Drug page: Doxycycline
doxycycline 80 mg/day, 12 weeks
Drug page: Doxycycline
doxycycline 160 mg/day, 12 weeks
Placebo, 12 weeks
Percentage Patients With Successful Outcome Investigator's Global Assessment (IGA) Score at Week 12, Intent to Treat (ITT) Population
IGA: 0/clear (clear skin no lesions, inflammatory or non-inflammatory), 1/almost clear (rare non-inflammatory lesion w/no more than 1 small inflammatory lesion), 2/mild (some non-inflammatory lesions with no more than a few inflammatory lesions, papules/pustules only, no nodular lesions), 3/moderate (up to many non-inflammatory lesions, some inflammatory lesions, no more than 1 small nodular lesion), 4/severe (many non-inflammatory \& inflammatory lesions, no more than a few nodular lesions. Lower score improvement in score. Success=IGA decrease of at least 2 grades from baseline score.
Time frame: Week 12
Absolute Change in Inflammatory Lesion Count From Baseline to Week 12, ITT Population
Change derived as Baseline evaluation minus the Week 12 evaluation. Thus a positive change reflects a reduction in lesion count. Inflammatory Lesion Count includes nodules, papules and pustules.
Time frame: Baseline to Week 12
Absolute Change From Baseline to Week 12 in NonInflammatory Lesion Count, ITT Population
Noninflammatory Lesion Count includes open and closed comedones.
Time frame: Baseline to Week 12
Absolute Change From Baseline to Week 12 in Total Lesion Count, ITT Population
Total Lesion Count is the sum of inflammatory and noninflammatory lesions.
Time frame: Baseline to Week 12
Recruitment began 4 Mar '08
| Milestone | Doxycycline 0.6 mg/kg/Day | Doxycycline 1.2 mg/kg/Day | Doxycycline 2.4 mg/kg/Day | Placebo Comparator |
|---|---|---|---|---|
| Started | 64 | 65 | 61 | 67 |
| Completed | 52 | 51 | 52 | 54 |
| Not completed | 12 | 14 | 9 | 13 |
IGA: 0/clear (clear skin no lesions, inflammatory or non-inflammatory), 1/almost clear (rare non-inflammatory lesion w/no more than 1 small inflammatory lesion), 2/mild (some non-inflammatory lesions with no more than a few inflammatory lesions, papules/pustules only, no nodular lesions), 3/moderate (up to many non-inflammatory lesions, some inflammatory lesions, no more than 1 small nodular lesion), 4/severe (many non-inflammatory \& inflammatory lesions, no more than a few nodular lesions. Lower score improvement in score. Success=IGA decrease of at least 2 grades from baseline score.
| Percentage of Participants | Doxycycline 0.6 mg/kg/Day | Doxycycline 1.2 mg/kg/Day | Doxycycline 2.4 mg/kg/Day | Placebo Comparator |
|---|---|---|---|---|
| Percentage Patients With Successful Outcome Investigator's Global Assessment (IGA) Score at Week 12, Intent to Treat (ITT) Population | 14.1 (6.6 to 25.0) | 15.4 (7.6 to 26.5) | 29.5 (18.5 to 42.6) | 16.4 (8.5 to 27.5) |
Change derived as Baseline evaluation minus the Week 12 evaluation. Thus a positive change reflects a reduction in lesion count. Inflammatory Lesion Count includes nodules, papules and pustules.
| Lesions | Doxycycline 0.6 mg/kg/Day | Doxycycline 1.2 mg/kg/Day | Doxycycline 2.4 mg/kg/Day | Placebo Comparator |
|---|---|---|---|---|
| Absolute Change in Inflammatory Lesion Count From Baseline to Week 12, ITT Population | 8.1 ± 13.2 | 11.5 ± 12.1 | 14.0 ± 19.7 | 7.3 ± 13.8 |
Noninflammatory Lesion Count includes open and closed comedones.
| Lesions | Doxycycline 0.6 mg/kg/Day | Doxycycline 1.2 mg/kg/Day | Doxycycline 2.4 mg/kg/Day | Placebo Comparator |
|---|---|---|---|---|
| Absolute Change From Baseline to Week 12 in NonInflammatory Lesion Count, ITT Population | 8.5 ± 19.1 | 5.2 ± 28.1 | 6.5 ± 16.2 | 1.8 ± 31.0 |
Total Lesion Count is the sum of inflammatory and noninflammatory lesions.
| Lesions | Doxycycline 0.6 mg/kg/Day | Doxycycline 1.2 mg/kg/Day | Doxycycline 2.4 mg/kg/Day | Placebo Comparator |
|---|---|---|---|---|
| Absolute Change From Baseline to Week 12 in Total Lesion Count, ITT Population | 16.6 ± 25.6 | 16.8 ± 32.7 | 20.5 ± 25.0 | 9.1 ± 38.1 |
Collected over 4 Mar 2008 thru 6 Nov 2008. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Doxycycline 0.6 mg/kg/Day | — | 0/64 (0%) | 22/64 (34.4%) |
| Doxycycline 1.2 mg/kg/Day | — | 0/65 (0%) | 20/65 (30.8%) |
| Doxycycline 2.4 mg/kg/Day | — | 0/61 (0%) | 29/61 (47.5%) |
| Placebo Comparator | — | 1/67 (1.5%) | 25/67 (37.3%) |
| Event | Doxycycline 0.6 mg/kg/Day | Doxycycline 1.2 mg/kg/Day | Doxycycline 2.4 mg/kg/Day | Placebo Comparator |
|---|---|---|---|---|
| Fracture (Left Radius)Injury, poisoning and procedural complications | 0/64 | 0/65 | 0/61 | 1/67 |
| Event | Doxycycline 0.6 mg/kg/Day | Doxycycline 1.2 mg/kg/Day | Doxycycline 2.4 mg/kg/Day | Placebo Comparator |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 0/64 | 1/65 | 8/61 | 2/67 |
| HeadacheNervous system disorders | 6/64 | 4/65 | 4/61 | 5/67 |
| VomitingGastrointestinal disorders | 1/64 | 1/65 | 4/61 | 0/67 |
| SunburnInjury, poisoning and procedural complications | 0/64 | 4/65 | 1/61 | 1/67 |
| DiarrheaGastrointestinal disorders | 3/64 | 2/65 | 2/61 | 0/67 |
| Pharyngolaryngeal PainRespiratory, thoracic and mediastinal disorders | 1/64 | 0/65 | 1/61 | 3/67 |
| GastroenteritisGastrointestinal disorders | 0/64 | 0/65 | 2/61 | 0/67 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/64 | 0/65 | 2/61 | 1/67 |
| NasopharyngitisRespiratory, thoracic and mediastinal disorders | 1/64 | 2/65 | 2/61 | 2/67 |
| Back PainMusculoskeletal and connective tissue disorders | 2/64 | 0/65 | 0/61 | 0/67 |
| Age Continuous(years) | Doxycycline 0.6 mg/kg/Day | Doxycycline 1.2 mg/kg/Day | Doxycycline 2.4 mg/kg/Day | Placebo Comparator | Total |
|---|---|---|---|---|---|
| Mean | 19.3 ± 5.2 | 19.4 ± 6.6 | 20.7 ± 7.4 | 20.2 ± 7.5 | 19.9 ± 6.7 |
| Age, Customized(Participants) | Doxycycline 0.6 mg/kg/Day | Doxycycline 1.2 mg/kg/Day | Doxycycline 2.4 mg/kg/Day | Placebo Comparator | Total |
|---|---|---|---|---|---|
| >= 18 years | 32 | 39 | 27 | 35 | 133 |
| < 18 years | 32 | 26 | 34 | 32 | 124 |
| Sex: Female, Male(Participants) | Doxycycline 0.6 mg/kg/Day | Doxycycline 1.2 mg/kg/Day | Doxycycline 2.4 mg/kg/Day | Placebo Comparator | Total |
|---|---|---|---|---|---|
| Female | 35 | 30 | 36 | 35 | 136 |
| Male | 29 | 35 | 25 | 32 | 121 |
| Region of Enrollment(participants) | Doxycycline 0.6 mg/kg/Day | Doxycycline 1.2 mg/kg/Day | Doxycycline 2.4 mg/kg/Day | Placebo Comparator | Total |
|---|---|---|---|---|---|
| United States | 64 | 65 | 61 | 67 | 257 |
The record gives a start of Feb 2008, a primary completion of Nov 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2011, 2 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Doxycycline